[Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)]. 1976

E M Kokoschka, and M Micksche

A prospective study was carried out on patients with stage I to III malignant melanoma. Following tumour resection these patients were treated with membrane extracts of autologous tumor tissue and BCG (Pasteur) or BCG alone by intradermal injections weekly for a minimum period of 6 months. They were followed up immunologically by delayed cutaneous hypersensitivity reactions: skin tests with recall antigens, PHA, with autologous tumour membrane extracts and challenge to 2-4-dinitrochlorobenzene (DNCB). The lymphocytic reactivity was assessed in vitro by means of the direct lymphocytic migration inhibition assay, purified tuberculin and autologous or allogoneic tumour extracts being used as antigens; the lymphocytic blastogenic response to PHA was also investigated. This study, which includes the data of 50 patients, demonstrates that it is possible to increase tumour--specific and general immune reactivity by this form of treatment.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D004137 Dinitrochlorobenzene A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds. 1-Chloro-2,4-Dinitrobenzene,2,4-Dinitrochlorobenzene,Benzene, 1-Chloro-2,4-Dinitro-,Chlorodinitrobenzene,DNCB,1 Chloro 2,4 Dinitrobenzene,2,4 Dinitrochlorobenzene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D001500 BCG Vaccine An active immunizing agent and a viable avirulent attenuated strain of MYCOBACTERIUM BOVIS, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. Bacillus Calmette Guerin Vaccine,Calmette Guerin Bacillus Vaccine,Calmette's Vaccine,Calmette Vaccine,Calmettes Vaccine,Vaccine, BCG,Vaccine, Calmette's

Related Publications

E M Kokoschka, and M Micksche
August 1997, Harefuah,
E M Kokoschka, and M Micksche
January 1989, Seminars in surgical oncology,
E M Kokoschka, and M Micksche
December 1977, Lijecnicki vjesnik,
E M Kokoschka, and M Micksche
March 1978, Annals of the Royal College of Surgeons of England,
E M Kokoschka, and M Micksche
January 1979, Archiv fur Geschwulstforschung,
E M Kokoschka, and M Micksche
October 1975, Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology,
E M Kokoschka, and M Micksche
September 1981, Schweizerische medizinische Wochenschrift,
E M Kokoschka, and M Micksche
March 1978, British medical journal,
E M Kokoschka, and M Micksche
July 1995, British medical bulletin,
E M Kokoschka, and M Micksche
September 1993, The Journal of dermatology,
Copied contents to your clipboard!